News

Explore

NovalGen enters strategic partnership with HALIX B.V. to manufacture clinical trial materials

22.02.2021

NovalGen announces updates to its executive management team

19.02.2021

Novalgen licenses mAbsolve’s QumAb™ technology to improve the safety of therapeutic antibodies

06.10.2020

Further reading

About us

NovalGen is an innovative clinical stage immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer.

About us

Contact us

Get in touch by or email

Contact us